Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Case Report

Acute Lung Injury with Amphotericin Infusion in a Patient with Invasive Mucormycosis

Author(s): Swapnil Tripathi, Durga Shankar Meena*, Deepak Kumar and Gopal Krishana Bohra

Volume 22, Issue 8, 2022

Published on: 26 August, 2022

Article ID: e190422203795 Pages: 4

DOI: 10.2174/1871526522666220419132741

Price: $65

Abstract

Background: Amphotericin B is a pivotal drug for the management of invasive fungal infections. However, it has a significant toxicity profile with acute infusion reactions like fever, chills, vomiting, anaphylaxis, and nephrotoxicity in patients with long-term use. Pulmonary reactions mimicking acute pulmonary edema are unusual with amphotericin.

Case Description: We report a case of a 51-year-old male diagnosed with rhinomaxillary mucormycosis, who developed acute onset breathlessness, bilateral diffuse pulmonary infiltrates after amphotericin infusion. The patient recovered spontaneously within a few hours after the cessation of amphotericin, which was parallel with the normalization of Chest X-ray. Furthermore, the Naranjo adverse reaction probability score was 9, which established a definite causal relation between drug use and adverse event.

Conclusion: Clinicians should be aware of acute lung injury in patients treated with amphotericin infusion. In cases with no alternative available, a slow infusion of amphotericin with close monitoring is required to prevent life-threatening pulmonary reactions.

Keywords: Amphotericin, antifungal, adverse drug reaction, infusion reaction, dyspnea, pulmonary infiltrates.

[1]
Laniado-Laborín R, Cabrales-Vargas MN, Amphotericin B. Side effects and toxicity. Rev Iberoam Micol 2009; 26(4): 223-7.
[http://dx.doi.org/10.1016/j.riam.2009.06.003] [PMID: 19836985]
[2]
Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351(14): 1391-402.
[http://dx.doi.org/10.1056/NEJMoa040446] [PMID: 15459300]
[3]
Noor A, Preuss CV, Amphotericin B, Amphotericin B. 2021 Jul 8. In: StatPearls. Treasure Island, FL: StatPearls Publishing 2021.
[4]
Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: Analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003; 36(10): 1213-20.
[http://dx.doi.org/10.1086/374553] [PMID: 12746764]
[5]
Ringdén O, Jønsson V, Hansen M, Tollemar J, Jacobsen N. Severe and common side-effects of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1998; 22(7): 733-4.
[http://dx.doi.org/10.1038/sj.bmt.1701406] [PMID: 9818706]
[6]
Collazos J, Martínez E, Mayo J, Ibarra S. Pulmonary reactions during treatment with amphotericin B: Review of published cases and guidelines for management. Clin Infect Dis 2001; 33(7): E75-82.
[http://dx.doi.org/10.1086/322668] [PMID: 11528589]
[7]
Bustamante-Ogando JC, Rivas-Larrauri F, Blancas-Galicia L, Otero-Mendoza F, Yamazaki-Nakashimada MA, Amphotericin B. Associated pulmonary complications in chronic granulomatous disease patients: Pulmonary complications in CGD. Pediatr Blood Cancer 2016; 63(10): 1871-2.
[http://dx.doi.org/10.1002/pbc.26080] [PMID: 27391767]
[8]
Hamill RJ. Amphotericin B formulations: A comparative review of efficacy and toxicity. Drugs 2013; 73(9): 919-34.
[http://dx.doi.org/10.1007/s40265-013-0069-4] [PMID: 23729001]
[9]
Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6(2): 154-64.
[http://dx.doi.org/10.1681/ASN.V62154] [PMID: 7579079]
[10]
Hardie WD, Wright PE, Bernard GR. Effects of intravenous amphotericin B infusion on hemodynamics and airway mechanics in awake sheep. Chest 1991; 99(2): 457-62.
[http://dx.doi.org/10.1378/chest.99.2.457] [PMID: 1989809]
[11]
Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304(20): 1185-9.
[http://dx.doi.org/10.1056/NEJM198105143042001] [PMID: 7219459]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy